Medires Publishers - Article

Abstract

India's burden of non-communicable diseases (NCDs) is escalating. NCDs typically present in individuals aged 55 years or older in many developed countries, but their onset occurs in India a decade earlier (≥45 years of age). The India GBD Collaborators showed that COPD and asthma made the second largest contribution to the total mortality burden of India, at 10·9%. The crude prevalence rates of asthma were 8.6% (6.1–11.4) in 1990-2016 period. Asthma is a major and common chronic noncommunicable disease (NCD), affecting both children and adults. Asthma affected an estimated 280 million people in 2022 and caused half a million deaths globally. India contributes to 12.9% of global asthma cases and 42.4% of global asthma deaths. The prevalence of asthma in the USA and UK is much higher, and so is the treatment adherence, mainly due to better diagnostic facilities and their use. The diagnosis of Asthma in Low- and middle-income countries (LMICs) is mostly by clinical examination that includes physical examination—use of stethoscope to hear typical wheezing—and lung function. Tests including peak flow meters and spirometers and chest X-rays to rule out pneumonia, TB, and lung cancer, and sinus X-rays to rule out rhinosinusitis. The management principles include 1) use of inhalers (powder or metered dose) for easing breathing, like Salbutamol, Levosalbutamol, and Terbutaline. 2) Controller medication Inhalers containing beclomethasone, budesonide, fluticasone, and mometasone. 3) Combination of both medications 4) Short courses of corticosteroids during asthmatic attacks. 5) Anti-IgE (omalizumab for patients with severe asthma). To comply with the WHO Global Action Plan for the Prevention and Control of NCDs and the United Nations 2030 Agenda for Sustainable Development, member countries have committed to improving the diagnosis, treatment, and monitoring of asthma to reduce the global burden of NCDs and to progress towards universal health coverage by 2030. This article reviews the situation of Asthma management in India in general and three case reports to describe the challenges of underdiagnosis and sustained treatment.

Introduction

India's burden of non-communicable diseases (NCDs) is escalating. NCDs typically present in individuals aged 55 years or older in many developed countries, but their onset occurs in India a decade earlier (≥45 years of age). The India GBD Collaborators showed that COPD and asthma made the second largest contribution to the total mortality burden of India, at 10·9%. The crude prevalence rates of asthma were 8.6% (6.1–11.4) in the 1990-2016 period [1]. Asthma is a major and common chronic noncommunicable disease (NCD), affecting both children and adults. Inflammation and narrowing of the small airways in the lungs cause asthma symptoms, which can be any combination of cough, wheeze, shortness of breath, and chest tightness. The symptoms are often worse at night or on waking from sleep. Usually, they resolve spontaneously or with the inhalation of a reliever medication. The exact cause of asthma is not yet understood, but there are multiple risk factors. Inhaled medicines can control symptoms and allow people to lead a normal, active life. Avoiding allergic triggers also helps to reduce asthma symptoms.[2]. Gastroesophageal disease (GORD), rhinosinusitis, and obstructive sleep apnea are associated medical conditions [2-11-12-13]. Asthma affected an estimated 262 million people in 2019 and caused 455,000 deaths globally. Most asthma-related deaths occur in low- and lower-middle-income countries due to underdiagnosis and under-treatment. [2]. It is included in the WHO Global Action Plan for the Prevention and Control of NCDs and the United Nations 2030 Agenda for Sustainable Development. WHO member countries have committed to improving the diagnosis, treatment, and monitoring of asthma to reduce the global burden of NCDs and to progress towards universal health coverage by 2030. [2] India contributes to 12.9% of global asthma cases and 42.4% of global asthma deaths. [2]

In the national NCD program the diagnostic tools recommended are:

i) physical examination—use of stethoscope to hear typical wheeze;

ii) chest X-ray to rule out Pneumonia, TB, and lung cancer;

 iii) sinus X-ray of sinuses to rule out rhinosinusitis.

3) Lung function test, including peak flow meter.

The management principles include

1) Use of inhalers (powder or metered dose) for easing breathing, which usually contain salbutamol, levalbuterol, and terbutaline.

2) Controller medication Inhalers containing beclomethasone, budesonide, fluticasone, and mometasone.

3) A combination of bronchodilators and preventive medications is also used.

4) Short courses of corticosteroids during asthmatic attacks.

5) Anti-IgE (omalizumab) is an approved treatment for patients with severe asthma that acts on decreasing serum IgE levels, as documented in effectively treating asthma.

The program recommends danger signs as

i) Asthma attacks not responding to inhalers, difficulty in talking due to breathing problems, and peak flow meter readings <50. According to recent international guidelines, patients with uncontrolled asthma require a prolonged maintenance treatment with a high dose of inhaled corticosteroids (ICS) in association with a long-acting β2-agonist (LABA) plus an oral leukotriene receptor antagonist (LTRA). The management of asthma is evolving to be more patient-specific due to better understanding of the biology of the development and progression of asthma. The addition of omalizumab, the first targeted biological treatment for asthma, has led to renewed optimism in the management of children and adolescents with atopic severe asthma[8]. The prevalence of asthma in developed countries like the USA and the UK is much higher, and so is the treatment adherence, mainly due to better diagnostic facilities and their use. While overall 25 million people (7.8% of the population) suffer from asthma in the USA in 2020[3], in the UK 5.4 million people (8%)[4]. The total burden of asthma in India is estimated to be 34.3 million, accounting for 12.9% of the global burden as of 20 June 2022. It was previously estimated that the prevalence of asthma in India was about 3%, with a prevalence of 2.4% in adults aged >15 years and between 4% and 20% in children. Overall prevalence in men was 5.9%, and among women, 8%. The urban prevalence was around 4.4% among men and women, whereas it was higher at 6.5% among rural men.[7] Childhood asthma is a leading cause of emergency department visits, hospitalizations, and missed school days. Unfortunately, it can't be cured, and symptoms mostly continue lifelong. The current study showed a significant reduction in the prevalence of current wheeze (p<0). The estimated prevalence of self-reported asthma in adult Indians based on analysis of 99,574 women and 56,742 men aged 20–49 years included in India’s third National Family Health Survey, 2005–2006, was 1.8% (95% CI 1.6–2.0) among men and 1.9% (95% CI 1.8–2.0) among women, with higher rates in rural than in urban areas and marked geographic differences. After adjustment for known asthma risk factors, women were 1.2 times more likely to have asthma than men. Daily/weekly consumption of milk/milk products, green leafy vegetables, and fruits was associated with a lower asthma risk, whereas consumption of chicken/meat, a lower body mass index (BMI; <16>30 kg/m², OR 1.67, 95% 95%CI 1.36–2.06), current tobacco smoking (OR 1.30, 95% CI 1.12–1.50), and ever use of alcohol (OR 1.21, 95% CI 1.05–1.39) were associated with an increased asthma risk[6]. Data from Indian centers that participated in the multicenter current Global Asthma Network showed a significant decline in symptoms of asthma compared to 2005 and 2013 studies. The most distressing inference was that almost 82% of current wheezers and 70% of subjects with symptoms of severe asthma were not clinically diagnosed as having asthma. The daily use of inhaled corticosteroids (ICS) was less than 2.5% in subjects with current wheeze and those with symptoms of severe asthma, but less than 1% used daily ICS when asthma remained undiagnosed[6]. Approximately 25 million people in the U.S. have asthma. This equals about 1 in 13 people. About 20 million U.S. adults aged 18 and older have asthma. Asthma is more common in female adults (9.8%) than male (6.1%) adults. It is a leading chronic disease in children. 2 Currently, there are about 5.1 million children under the age of 18 with asthma. Asthma is more common in male (8.4%) children than female children (5.5%). In 2019, 44.3% of children aged 18 and younger who had asthma reported having one or more asthma attacks in the past year. About 47.2% of children under the age of 5 with asthma had an attack. According to the Centers for Disease Control and Prevention (CDC), asthma attacks in children have declined from 2001 through 2019. 3 Even though asthma is controllable, it is estimated that 50% of children with asthma have uncontrolled asthma[2]. The data from national and state surveillance systems administered by the Centers for Disease Control and Prevention (CDC) indicate a prevalence of asthma to be 8% of adults over 18 years and 7% for children under 18 years in the USA. The highest prevalence was among 20–24-year-olds, and the lowest prevalence was 2.6% among 0–4-year-old children. After the age of 5 years, it remained between 7 and 10% of each age cohort, and the elderly population (>65 years) had a prevalence rate of 7.7%. Overall, females had a higher prevalence of 8.9% when compared to men at 6.6%. The gender difference was more pronounced among boys (8.8%) under 18 years compared to girls under 18 years (5.5%). Among the adults the trend was reversed, as women had 9.8% and men 6.6%[5]. National Prevalence of Asthma Attacks among People with Current Asthma by Age (2020) indicates a total surveyed of 10,342,170 asthmatics, 41%. Children (<18) A leading lung charity warned in September 2022 that there are 5.4 million out of an estimated 67.5 million (8%) people in the UK with asthma[4].

Case Report

1. Carcinoid Tumor Confusing Br. Asthma:

Uncontrolled symptoms that lingered despite aggressive asthma therapy warranted evaluation, resulting in a carcinoid tumor in the left bronchus, and a left lower lobectomy helped in relieving the asthma to a status of medical management. Way back during my internship in 1983, a 48-year-old village woman, a housewife, was admitted to our medical college hospital complaining of wheezing and dyspnea in the midnight. Suspecting status asthmaticus, we got the physician to examine her and put her on IV corticosteroids for detailed investigation the next day. She had been diagnosed with asthma 12 years previously and was well controlled using budesonide at 160 μg + formoterol at 4.5 μg b.i.d. combination therapy until 5 months before her visit to our hospital. She had had a severe asthma attack at that time, during which her wheezing was not well correlated with physical exercise and had persisted for several months. She was treated unsuccessfully with budesonide at 320 μg + formoterol at 9 μg b.i.d. combination, montelukast at 10 mg/day, and oral steroids (30–40 mg/day of prednisolone) during that period, and because her asthma had failed to come back under control, she was referred to our hospital and hospitalized for evaluation for anti-IgE therapy. On examination her vitals were stable with a heart rate of 76 bpm, a temperature of 36.5°C, blood pressure of 110/70 mmHg, and a respiratory rate of 28/min on physical examination. Her examination was normal except for decreased auscultation in the left lung. The next day her routine blood count was hematocrit, 40%; leukocyte, 10300; and erythrocyte sedimentation rate, 15 mm/hr. Spirometry showed an obstructive pattern (forced expiratory volume in 1 second [FEV1], 2.20 L [82%]; forced vital capacity [FVC], 3.45 L [110%]; FEV1/FVC, 60%). We were unable to show spirometry reversibility. Her skin-prick test was positive for house-dust mites. Total IgE level was 115 kU/L. All data about the patient seemed to indicate that she could be a candidate for anti-IgE therapy. The routine chest radiography revealed a left-sided hilar opacity. A CT scan showed a 10-mm nodular lesion located in the left lower lobe bronchus. These radiological findings changed our management plan and diagnosis from asthma to a chest mass. A fiberoptic bronchoscopy was performed, which revealed an endobronchial lesion obstructing the left lower bronchus lumen. Biopsy was not performed for fear of a risk of bleeding. The cytological examination of bronchoalveolar lavage fluid removed from the left bronchus was normal. The patient was transferred to the thoracic surgery ward for surgical treatment. She underwent a left lower lobectomy and mediastinal lymph node dissection. Histopathological examination revealed an intrabronchial tumor, made up of monotonous cells with finely granular nuclei and eosinophilic cytoplasm. No mitotic figures or necrosis were detected. After surgical resection, she was asymptomatic with budesonide at 160 μg + formoterol at 4.5 μg combination therapy and had a better pulmonary function (FEV1, 2.53 L [95%]; FVC, 4.29 L [138%]; FEV1/FVC, 59%).

2. Master Krishna – 8 yrs. old, male.

17/10/2022, brought to emergency admission with C/O cough, difficulty in breathing, and tightness in chest. He was diagnosed as asthmatic 2 years ago, and in the last 6 days the shortness of breath increased, compelling parents to get him to emergency care.

Family history did indicate either the parents or 4 years old- er sister suffering from Asthma. On physical examination he was average built boy, with about 25 Kg weight, 120 Cm height, Pulse-100/min, RR- 30/min, BP-90/60. Total IgE was 480, KU/Litre as against a normal range of 400, ESR was elevated at 25/hr against upper limit of 20, and Chest Xray was normal. He was put on I V drip and though which antibacte- rial Ceftriaxone 1G was pushed twice /day Syrup Erythromycin200 mg was given twice orally, along with Budecort and Asthalin inhalers 2 puffs each at a time twice a day). Sodium chloride nasal drops 2 ml each for clearing the nose was also given every 4 hours. A study nearly seven years ago, the Respiratory Foundation of India through the chest disease screening camps organ- ised by Rotary International had reported an incidence of 5 to 7% in the urban population. However, in the last five to six years, this has doubled to 10 to 15% in the city of Chennai[8]. When children travel to school in the morning, they must go through the traffic on the road and are exposed to dense smoke and pollution. The mushrooming of flats system is contributing to increased pollution. Other factors such as dust, mites, and seasonal viral infections are contributing to the increase in cities like Mumbai, Delhi, Bengaluru, Chennai, Kolkata, etc. The use of steroid inhalers for asthma had gone up, indicating better acceptance levels among the people. What is disheartening is that patients do not take inhalers regularly, thinking that inhalers unsafe, may become addiction-prone treatments, and cause growth stunting in children. Currently, the compliance level of steroid inhalers is around 15 to 20% only[8]

3. ALLERGY BULLYING leading to Asthma:

A 10-year-old girl with a history of asthma presented to the emergency department with a three-day history of increased work of breathing, cough, and wheezing since early morning on 8 December 2023, a chilly day. She reported no clear trigger for her respiratory symptoms, although she had noted some symptoms of a mild upper respiratory tract infection. With this episode, the patient had been using a short-acting bronchodilator more frequently than she had in the past, without the expected resolution of symptoms. On the day of the presentation, the patient awoke feeling ‘suffocated,’ and her mother noted her lips to be blue. In the emergency department, her oxygen saturation was 85%, and her respiratory rate was 40 breaths/min. She had significantly increased work of breathing and poor air entry bilaterally to both lung bases, with wheezing in the upper lung zones. She was treated with salbutamol/ipratropium, intravenous steroids& magnesium sulfate. Her chest x-ray showed hyperinflation and no focal findings. The patient's asthma exacerbation resolved with conventional asthma treatment. Her pulmonary function tests were nonconcerning (FEV 1 - 94% and 99% of predicted) after her recovery. Her medical history revealed that she was followed by a respirologist for her asthma, had good medication adherence, and had not experienced a significant exacerbation for six months. She also had a history of wheezing, dyspnoea, and pruritis with exposure to peanuts, chickpeas, and lentils, for which she received epinephrine injections. In the past, her wheezing episodes had been seasonal and related to exposure to grass and pollen. After a long counselling, the patient later revealed that she had been experiencing significant bullying at school, as her classmates had smeared peanut butter on one of her cheeks. She developed pruritus and immediately started wheezing and coughing later that day. This event followed several months of being taunted with peanut products at school. The patient was experiencing low mood and reported new symptoms of anxiety related to school. The trigger for her asthma exacerbation was likely multifactorial, related to exposure to the food allergen as well as the upper respiratory infection. Population-based studies have shown that 20% to 35% of children with allergies experience bullying. In many cases this bullying is related directly to the food allergy[9].

Discussions

Pathophysiology—What Happens in an Attack:

i) Bronchospasm: The muscles around the airways constrict, making airways narrow, and air cannot flow freely through constricted airways.

ii) Inflammation:

The lining of the airways becomes swollen and doesn’t let as much air in or out of your lungs.

iii) Mucus production:

During the attack, our body creates more mucus, which clogs airways

Types of Asthma

Asthma is classified into types based on the cause and the severity of symptoms [6].

For management purposes the healthcare providers identify asthma as

1. Intermittent: This comes and goes; the patient feels normal in between asthma flares.

2. Persistent: In such cases symptoms, whether mild, moderate, or severe, persist much of the time.

How well the patient does during an attack is also considered. Academic classification based on the causes and onset includes:

1. Allergic: Some people’s allergies can cause an asthma attack. Allergens include molds, pollens, and pet dander.

2. Non-allergic: Outside factors like exercise, stress, illness, and weather may cause a flare.

Based on onset time Asthma can be:

1. Adult-onset: This type of asthma starts after the age of 18.

2. Pediatric: Childhood asthma begins before the age of 5 and can occur in infants and toddlers. Children may outgrow asthma. Doctors should decide whether a child needs to have an inhaler available in case of an asthma attack.

Other types of asthma include

Exercise-induced asthma: Triggered by exercise-induced bronchospasm.

Occupational asthma: This asthma happens primarily to people who work around irritating substances.

Asthma-COPD overlap syndrome (ACOS): This type hap- pens when you have both asthma and chronic obstructive pulmonary disease (COPD). Both diseases make it difficult to breathe.

Cough Variant asthma: The only symptom is persistent cough

Diagnosis of Asthma:

Asthma is a clinical diagnosis, based on a history of characteristic symptom patterns and evidence of variable expiratory airflow limitation. In well-resourced healthcare settings, this evidence is derived from spirometry with bronchodilator responsiveness—“reversibility” testing or bronchial provocation challenge testing. The differential diagnosis of asthma includes endemic respiratory diseases like tuberculosis, HIV/AIDS, and parasitic or fungal lung diseases. Clinicians place greater reliance on clinical findings and often use syndromic approaches to diagnosis and management. In LMICs, like India, even when available, these investigations are still substantially underused (unaffordable or time-consuming in special clinics), and more than one test is often required to confirm airflow variability.

By measuring how fast you're able to breathe out, your peak flow score can indicate whether your airways are narrowed. Peak expiratory flow (PEF) is measured in liters per minute. Normal adult peak flow scores range between around 400 and 700 liters per minute, although scores in older women can be lower and still be normal. FEV1 = forced expiratory volume in one second; PEF = peak expiratory flow.

7-inch Touchscreen, all-in-one Spirometer with embedded printer, real-time test also available on PC via USB and Bluetooth. Perfect suite in hospitals and asthma camps, with its fast and silent built-in thermal printer with customizable printout format. Lightweight for easy mobility, carrying case included, long life Rechargeable Battery.

Features of our 3-Ball Spirometer: Color-coded balls in each of the three chambers prove to be a visual incentive to the patient. Air flows into a single channel; when it passes through the chamber, it raises each of the three balls depending on the flow inhaled per second. Connect the tube with the 12 mm OD connector and mouthpiece. Flow rates of 600 ml/sec, 900 ml/sec, and 1200 ml/sec by using different colors of balls for easy identification of the flow rates. Can be disassembled into parts for cleaning and disinfection. Deep Breathing Exerciser for comprehensive respiratory fitness. Helps achieve optimum lung capacity and restore disrupted breathing patterns.

Association Between Asthma and Obstructive Sleep

Asthma and obstructive sleep apnea (OSA) are the commonest pulmonary diseases worldwide and contribute to significant morbidity and mortality. Indian studies have identified a high prevalence of OSA among patients of moderate to severe asthma, which negatively affects quality of sleep and asthma control, which further leads to poor quality of life in these patients. One study inferred that the apnea-hypopnea index (AHI) >5/h was found in 15/30 (50%) cases with moderate and severe asthma (N=15 each). In moderate asthma 6/15 (40%) and in severe asthma 9/15 (60%) were diagnosed to have OSA.[11]

Association Between Asthma and Gastroesophageal disease (GERD)

Asthma and acid reflux often occur together in children as well as in adults. It's known that asthma and acid reflux (especially the severe form known as gastroesophageal reflux disease (GERD)) worsen each other. The prevalence of GERD is estimated to be around 30-80% among asthmatics. The proposed mechanisms of GERD-induced asthma include a vagally mediated reflex, microaspiration, and altered immune activity. In simple terms, GERD causes asthma-like symptoms by two mechanisms: -i) Aspiration of acid particles cles in the trachea cause coughing, wheezing, and pneumonia. ii) Acid in the esophagus causes a reflex phenomenon in the trachea, triggering asthma-like symptoms. This study stresses the need for patients with asthma to be evaluated for gastroesophageal reflux and to be treated with aggressive anti-reflux therapy to reduce morbidity. Coexistence of allergic rhinitis and asthma in Indian patients There is enough evidence of coexistence of allergic rhinitis (AR) and asthma (AS) through the (CARAS) survey, and it reinforces the need for early diagnosis and guideline-based management of AR in patients with asthma. The study of 1161 asthma patients with a mean age of 40.41 [±17.05] years showed the prevalence of coexisting AR was found to be 65.24%, with the highest prevalence (80%) in the southern regions of India. Sneezing (71.78%), followed by watery, runny nose (63.59%), were the most common AR symptoms. The majority (72.32%) of the patients had seasonal AR. Coexistence of AR and asthma was significantly associated with the presence of personal and family history of atopy. Smoking, exposure to biomass fuel, and the presence of pets and animals at home were also significantly associated with AR-asthma coexistence. The usage of oral steroids was significantly higher, as 66% of patients were prescribed intranasal corticosteroids[13].

Summary

Asthma is a major and common chronic noncommunicable disease (NCD), affecting both children and adults globally. India contributes to 12.9% of global asthma cases and 42.4% of global asthma deaths. Data from Indian centers that participated in the multicenter current Global Asthma Network showed a significant decline in symptoms of asthma compared to 2005 and 2013 studies. An estimated 35 million people are suffering from asthma in 2023. Asthma is a clinical diagnosis, based on a history of characteristic symptom patterns and evidence of variable expiratory airflow limitation. In well-resourced healthcare settings, evidence is derived from spirometry with bronchodilator “reversibility” testing. Investigations like chest X-rays and sinus X-rays are used in complex cases to differentiate TB, rhinosinusitis, and lung cancers, as they are scarcely available and are substantially underused (unaffordable or time-consuming in special clinics), and more than one test is often required to confirm airflow variability. The most distressing situation is that 82% of current wheezers and 70% of subjects with symptoms of severe asthma are not clinically diagnosed as having asthma. The daily use of inhaled corticosteroids (ICS) is 2.5% in subjects with current wheeze and those with symptoms of severe asthma, but less than 1% used daily ICS when asthma remained undiagnosed. All-out efforts need to be made to improve early diagnosis and continuous use of inhalers to minimize the complication and lead to an almost normal and active life.

Conflict of Interest

The author declares no conflict of interest

References

1. Song, Peige, Davies Adeloye, Hani Salim, Jhonathan Pr Dos Santos, Harry Campbell, Aziz Sheikh, and Igor Rudan. "Global, regional, and national prevalence of asthma in 2019: a system- atic analysis and modelling study." Journal of global health 12 (2022): 04052.
   View at Publisher | View at Google Scholar
2. Kumar, Ashwani, S. G. Khandelwal, and Yau Yuan-Yeu. "Chal- lenges of Climate Change with the Era of Covid-19." (2021): 193-199.
   View at Publisher | View at Google Scholar
3. Mirra, Virginia, Silvia Montella, and Francesca Santamaria. "Pediatric severe asthma: a case series report and perspec- tives on anti-IgE treatment." Bmc Pediatrics 18 (2018): 1-11.
   View at Publisher | View at Google Scholar
4. Stats on lung health
   View at Publisher | View at Google Scholar
5. 2019 Archived National Asthma Data.
   View at Publisher | View at Google Scholar
6. Singh, Sheetu, Sundeep Salvi, Daya Krishan Mangal, Meenu Singh, Shally Awasthi, Padukudru Anand Mahesh, Sushil K. Kabra et al. "Prevalence, time trends and treatment practic- es of asthma in India: the Global Asthma Network study." ERJ open research 8, no. 2 (2022).
   View at Publisher | View at Google Scholar
7. Agrawal, S., N. Pearce, and S. Ebrahim. "Prevalence and risk factors for self-reported asthma in an adult Indian population: a cross-sectional survey." The international journal of tuberculo- sis and lung disease 17, no. 2 (2013): 275-282.
   View at Publisher | View at Google Scholar
8. Kishanrao, Suresh. "Asthma in India." International Journal of Pulmonology and Disorders 1, no. 1 (2023).
   View at Publisher | View at Google Scholar
9. Asthma cases in Chennai double in 5 years - The Hindu.Septem- ber05,2018.https://www.thehindu.com/news/national/tamil-na- du/asthma-cases-in-city-double-in-5-years/article24866869. ece#:~:text=Outdoor%20pollution%20considered%20the%20 primary%20cause&text=The%20incidence%20of%20asth- ma%20has,stress%20on%20improving%20public% 20trans- portation
   View at Publisher | View at Google Scholar
10. Das, Lopamudra, and Michelle GK Ward. "Case 1: A 12-year- old girl with food allergies and an acute asthma exacerbation." Paediatrics & Child Health 19, no. 2 (2014): 69.
    View at Publisher | View at Google Scholar
11. Priya, Anshu, Nitin Goel, Kamal Singh, and Raj Kumar. "Asso- ciation Between Asthma and Obstructive Sleep Apnoea." Indi- an J Chest Dis Allied Sci 63, no. 2 (2021): 95-99.
    View at Publisher | View at Google Scholar
12. S. Charles, P. Johnson, R. P. Rajagopalan, A.S. Subhashini, A. P. Kumar, 2011. The Prevalence of the Gastro Oesophageal Reflux Disease in Asthmatics. Journal of Clinical and Diagnos- tic Research. 2011 August, Vol-5(4): 711-713.
    View at Publisher | View at Google Scholar